Why KalVista Pharmaceuticals Stock Skyrocketed 115% Today

1 min read

Shares of KalVista Pharmaceuticals (NASDAQ: KALV) soared 115% on Tuesday after the pharmaceutical company released promising results from its phase 2 clinical trial for KVD900, its oral drug for hereditary angioedema (HAE) attacks. 

KalVista’s study showed that 15% of the patients who were treated with KVD900 within one hour of experiencing a swelling attack required rescue medication, compared to 30% of those who received a placebo. KVD900 also appeared to be generally safe and well-tolerated, with no serious adverse events reported.

KalVista Pharmaceuticals’ stock price surged on Tuesday. Image source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

NCR (NCR) Q4 2020 Earnings Call Transcript

Next Story

Alteryx (AYX) Q4 2020 Earnings Call Transcript

Latest from Blog